As the cornerstone of the Human Milk Oligosaccharide (HMO) family, 2'-fucosyllactose (2'-FL) represents the most abundant trisaccharide in human breast milk, accounting for nearly 30% of the total HMO profile. Unlike traditional prebiotics, 2'-FL is a complex carbohydrate that serves as a high-value bioactive ingredient with transformative potential in neonatal nutrition and adult therapeutic sectors. CD BioGlyco provides an industry-leading 2'-FL production service, leveraging synthetic biology and precision fermentation to bypass the limitations of chemical synthesis and animal-source extraction. Our platform focuses on the high-titer biosynthesis of high-purity 2'-FL, ensuring a sustainable, scalable, and bio-identical supply for global research and industrial applications. By integrating metabolic engineering with advanced downstream processing, we empower clients to incorporate the gold standard of HMOs into their product pipelines.
Core Technologies
We utilize a multi-layered technological approach to maximize 2'-FL yield and purity:
Modular Metabolic Engineering
We refactor microbial pathways by overexpressing the de novo GDP-L-fucose synthesis route (ManB, ManC, Gmd, and WcaG) while optimizing α-1,2-fucosyltransferase (FT) activity.
Orthogonal Energy Modules
Our Pichia pastoris and E. coli chassis are engineered with enhanced NADPH and GTP regeneration modules, significantly reducing metabolic burden during large-scale fermentation.
Substrate Flux Optimization
We employ gene editing-mediated gene knockouts (e.g., ΔlacZ, ΔwcaJ, ΔfucK) to eliminate competing pathways, ensuring maximal carbon flux is directed toward 2'-FL synthesis rather than biomass or byproduct formation.
Precision Fermentation Control
Real-time monitoring of pH, dissolved oxygen, and substrate feeding profiles allows for high-density cultivation and superior batch-to-batch consistency.
Where Science Delivers Nature's Signature
Custom Chassis Development: Engineering of specialized microbial factories tailored to specific regulatory environments or carbon source preferences.
High-Titer Biosynthesis: Large-scale production of 2'-FL with yields exceeding industry benchmarks (up to 65+ g/L in fed-batch systems).
Isotope-Labeled 2'-FL: Production of stable isotope-labeled 13C or 15N 2'-FL for advanced metabolic tracing and pharmacokinetic studies.
Structural Characterization: Comprehensive analytical services for structural verification and purity assessment of synthesized HMOs.
Workflow
Strain Design & Construction
We begin by selecting a microbial host that aligns with both high productivity and regulatory compliance. Within this host, we construct an efficient biosynthetic pathway for 2'-FL. This involves the stable genomic integration or plasmid-based expression of codon-optimized genes encoding key enzymes, primarily α-1,2-fucosyltransferases (e.g., FutC from Helicobacter pylori), to ensure high translational efficiency and enzyme activity in the chosen chassis. The pathway is designed to efficiently channel central metabolites towards 2'-FL synthesis.
Pathway Fine-Tuning
To maximize flux towards the target product and minimize the accumulation of intermediates or metabolic burden, we precisely balance the expression of all pathway genes. This is achieved by employing libraries of synthetic promoters and ribosomal binding sites (RBS) of varying strengths. We systematically tune the expression levels of the "donor module" enzymes responsible for synthesizing the activated sugar nucleotide GDP-L-fucose (e.g., from GDP-D-mannose) and the "acceptor module" involving lactose transport/intracellular availability, as well as the final fucosyltransferase. This combinatorial approach resolves metabolic bottlenecks and optimizes resource allocation within the cell.
Lab-Scale Pilot Fermentation
Initial bioprocess development is conducted in bench-top bioreactors. This stage focuses on establishing baseline titers, yield, and productivity. We critically evaluate and optimize key fermentation parameters, including the carbon source feeding strategy (comparing glucose, glycerol, and fructose for their effects on growth, metabolism, and product formation), induction timing, pH, dissolved oxygen, and temperature. The goal is to define a robust and scalable cultivation profile that supports efficient 2'-FL production.
Process Scaling
Strains demonstrating high performance at the lab scale are transferred to our pilot-scale fermentation platforms. Here, we implement and refine high-density fed-batch cultivation strategies designed to achieve cell densities and product concentrations relevant for industrial manufacturing. Scale-up studies focus on maintaining optimal physiological conditions, managing mass transfer (oxygen, nutrients), and controlling foam and heat generation. The process is optimized for volumetric productivity (g/L) and overall yield to ensure economic viability.
Downstream Purification
The harvest broth containing 2'-FL undergoes a proprietary, multi-step purification process to remove cells, media components, by-products, and colorants. The sequence typically begins with membrane filtration (microfiltration/ultrafiltration) for cell separation and clarification. This is followed by chromatographic steps, such as ion-exchange chromatography, to remove charged impurities. A key polishing step involves activated carbon treatment for decolorization and removal of trace organic contaminants. The process is designed to be efficient and scalable, resulting in a syrup or powder with a purity exceeding 98%.
Quality Validation
The final 2'-FL product is subjected to a comprehensive battery of analytical tests to ensure safety, identity, purity, and potency. Structural confirmation is achieved using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and nuclear magnetic resonance (NMR) spectroscopy. Purity is quantified via high-performance liquid chromatography (HPLC). Additional tests screen for and quantify any potential microbial contaminants (bioburden, endotoxins) and allergens. This rigorous quality control protocol guarantees a product that meets all specified regulatory and customer requirements.
Publication Data
Journal: Frontiers in Bioengineering and Biotechnology
DOI: 10.3389/fbioe.2025.1569597
IF: 4.8
Published: 2025
Results: In this study, the authors developed an efficient microbial platform for the production of 2'-FL, a prominent human milk oligosaccharide with significant health benefits. They engineered E. coli C43 (DE3) by introducing a novel α-1,2-fucosyltransferase (FutCB) from Bacillus cereus to catalyze the key fucosylation step. To enhance precursor availability, strategic gene knockouts (lacZ and waaF) were combined with the overexpression of enzymes involved in the de novo synthesis of GDP-L-fucose (e.g., gmd, manB, wcaG, manC). The implementation of constitutive promoters ensured stable and inducer-free expression during fed-batch fermentation, optimizing the biosynthetic pathway. This approach yielded an impressive 2'-FL titer of 121.4 g/L within 64 hours, achieving a production rate of 1.90 g/L/h, which surpasses previous reports. The research demonstrates a scalable and cost-effective strategy for 2'-FL biosynthesis, highlighting its potential for industrial application while providing a foundation for further metabolic engineering refinements.
Application
Infant Formula Optimization
2'-FL is the primary ingredient used to narrow the nutritional gap between bovine milk-based formula and human breast milk, supporting neonatal development.
Gut Microbiome Therapeutics
Used as a precision prebiotic to selectively stimulate the growth of Bifidobacterium infantis and other beneficial commensals in both infants and adults.
Immune System Modulation
2'-FL acts as a decoy receptor for enteric pathogens, significantly reducing the risk of respiratory and gastrointestinal infections in vulnerable populations.
Neurodevelopment Research
Emerging studies suggest 2'-FL plays a role in the gut-brain axis, potentially enhancing cognitive function and memory during early developmental stages.
Advantages
Scalable Industrial Platform
Our infrastructure is designed for rapid scale-up from milligram research samples to multi-kilogram pilot batches without compromising quality.
Enhanced Microbial Safety
We prioritize the use of non-pathogenic, phage-resistant strains, making our 2'-FL ideal for sensitive applications like infant formula.
Sustainability
Our microbial fermentation process significantly reduces the environmental footprint compared to chemical synthesis, which often relies on toxic reagents.
Custom Carbon Source Utilization
Our strains can be adapted to utilize various feedstocks, including glucose, fructose, or glycerol, depending on client cost requirements.
Frequently Asked Questions
Customer Review
"CD BioGlyco delivered 2'-FL of exceptional purity for our pathogen-adhesion studies. Their technical expertise in HMO biosynthesis is truly world-class."
– Dr. J.L., Senior Scientist, Immunology Department
"Switching to CD BioGlyco for our 2'-FL supply significantly improved our formula's stability. The consistency across batches has been impressive."
"The metabolic engineering services provided by CD BioGlyco allowed us to test unique 2'-FL analogs that were previously unavailable. Highly recommended for custom glycan work."
– Dr. K.M., Lead Researcher, Microbiome Research
"The data package provided with our HMO order was comprehensive, making our regulatory submission process much smoother. Their team understands the science behind the sugars."
– Dr. T.H., Principal Investigator, Gastroenterology
Associated Services
A-Tetrasaccharide Antigen Production
Specialized synthesis of complex glycan antigens for vaccine development.
B-Tetrasaccharide Antigen Production
Precision production of blood group antigens for diagnostic and therapeutic applications.
A-Trisaccharide Antigen Production
Targeted synthesis service of trisaccharide motifs for immunological profiling.
CD BioGlyco is dedicated to advancing the field of glycan biotechnology through our specialized 2'-FL production service. By combining cutting-edge synthetic biology with scalable fermentation, we provide the high-purity HMOs essential for the next generation of health and nutrition products. Whether you are conducting fundamental research or launching a commercial product, CD BioGlyco is your trusted partner for high-performance glyco-solutions. For detailed information on our production capabilities or to request a quote for your project, please contact us. We are ready to assist you in bringing your HMO-based innovations to life.
Reference
Zhang, K.; et al. Intensification of 2'-fucosyllactose biosynthesis pathway by using a novel fucosyltransferase from Bacillus cereus. Frontiers in Bioengineering and Biotechnology. 2025, 13: 1569597. (Open Access)
For research use only. Not intended for any clinical use.
